Recent Development News: Q4 – 2017

Clinical Data for X4P-001-IO in Combination with Inlyta® (Axitinib) Demonstrated Encouraging Overall Response Rates (including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhibitor to improve immune cell trafficking to treat cancer and rare diseases, today announced updated results from the Phase 1 part of an ongoing Phase 1/2 study of X4P-001-IO … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Dr. David C. Dale, MD will present the first clinical data from an ongoing … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals Secures $27 Million in Series B Financing

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced the successful completion of a $27 million Series B financing. Proceeds from the financing will … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today highlighted data from multiple presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

First Clinical Data from Combination of X4P-001- IO and Keytruda® (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced that the first data from its ongoing Phase 1b clinical study of X4P-001-IO in patients … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off